Microgravity for Personalised Medicine (M4PM) is a programme focused on 3D Tumour, Organoid and Spheroid growth in microgravity, to enable the development of space-based Personalised Medicine. Led by Space Applications Services and co-financed by the European Space Agency, the project aims to create both a technical model as well as a business model that replicates and enhances traditional terrestrial ones.
M4PM envisions a future where space-based research revolutionizes drug discovery and personalised medicine. By leveraging microgravity, we aim to overcome the limitations of traditional in-vitro models, accelerating the development of more effective treatments and improving patient outcomes worldwide.
Our mission is to harness the unique environment of space to cultivate high-quality 3D organoids, spheroids, and tumours for advanced disease modeling, drug screening, and personalised medicine. Through cutting-edge research and international collaboration, we strive to push the boundaries of biomedical science and create new opportunities for pharmaceutical and biotechnology advancements.
The way microgravity affects the behaviour and development of living organisms allows for research that cannot be conducted on Earth. The goal of the M4PM initiative is to evolve into an end-to-end service for growing high quality 3D tumours, organoids and spheroids in low shear conditions in Space, to better address certain health and medical challenges.
Space-grown tumours, organoids and spheroids will be used for a wide range of applications and research areas including:
The first step towards these goals is building an international community of key thought leaders that would bring their knowledge, expertise and ideas to ignite and fuel the discussion. With microgravity representing the next frontier for life sciences, pharma & biotech, chemical industry, academic research institutes, incubators and accelerators, will all benefit from the availability of high-quality space-grown 3D tumours, organoids and spheroids.
The M4PM project is led by Space Applications Services and co-financed by the European Space Agency. In this endeavour, we have partnered with OrganoTherapeutics in the role of pilot customer, aiming for a demo mission in late 2026.
We will be attending a number of events which may provide the opportunity to meet and connect.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.